Mitralign is focused on developing a catheter-based technology for the percutaneous treatments of functional mitral regurgitation.
Mitralign is a venture backed privately held company located in a suburb of Boston, MA. The company is developing an innovative catheter based technology for percutaneous treatment of functional mitral regurgitation. The novel Mitralign system emulates surgical annuloplasty as it delivers a series of surgical implants directly into the mitral annulus by means of a catheter. The implants are cinched together, thus reducing the size of the mitral valve annulus and the valve opening.Mitralign is funded by top tier venture capitalists and has two major cardiovascular device companies as investors.
Announced Date | Round | Money Raised | Number of Investors | Lead Investors | Post Valuation | |
---|---|---|---|---|---|---|
May 16, 2012 | Series D | $35M | 1 | — | — | Detail |
Dec 31, 2007 | Series C | $24M | 1 | Medtronic | — | Detail |
Jun 30, 2006 | Series B | $13M | 1 | — | — | Detail |
Jun 8, 2005 | Series Unknown | $6.70M | 1 | — | — | Detail |
May 10, 2004 | Series A | $3.50M | 1 | — | — | Detail |
Investor Name | Lead Investor | Funding Round |
---|---|---|
Medtronic | — | Series D |
Accelerated Technologies Partners | — | Series B |